Welcome to our dedicated page for Radiopharm Theranostics American Depositary Shares news (Ticker: RADX), a resource for investors and traders seeking the latest updates and insights on Radiopharm Theranostics American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Radiopharm Theranostics American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Radiopharm Theranostics American Depositary Shares's position in the market.
Radiopharm Theranostics (NASDAQ:RADX) has secured a US$5.0 million (A$8.0 million) private placement from Lantheus Holdings Inc., strengthening their strategic partnership. The placement consists of 133 million shares at A$0.060 per share, representing a significant 150% premium to the last traded price of A$0.024.
Following this investment, Lantheus becomes Radiopharm's largest shareholder, increasing its stake to 12.16% of the company. The placement replaces 6-month options issued in August 2024, with settlement expected within 7 days. The funds will be directed towards developing Radiopharm's clinical pipeline in oncology radiopharmaceuticals.
Radiopharm Theranostics (ASX:RAD) has entered into a strategic co-development partnership with Lantheus to advance clinical development of radiopharmaceuticals in Australia. The collaboration will initially focus on a basket clinical trial targeting multiple solid tumors. Under the agreement, Lantheus will cover all clinical development costs, and Radiopharm will receive up to USD 2 million in milestone payments for achieving key objectives in the first imaging trial, including ethics committee approval, first patient dosing, and completion of patient enrollment. Radiopharm will lead the clinical development efforts in Australia, leveraging its infrastructure and experience in the field.
Radiopharm Theranostics (ASX:RAD) has received ethics approval in Australia to initiate a Phase 1 First-In-Human therapeutic trial of 177Lu-RAD202 for treating HER2-expressing solid tumors. The open-label trial, named 'HEAT' (HER2 Antibody Therapy with Lutetium-177), will evaluate safety and preliminary clinical activity in patients with HER2-expressing advanced cancers.
The multicenter study follows previous successful data showing safety and biodistribution of 99mTc-labeled RAD 202 in humans. Preclinical findings with 177Lu-labeled RAD 202 demonstrated tumor growth inhibition and significantly prolonged survival time in HER2-positive xenografts. The treatment targets HER2, which is overexpressed in breast cancer and other solid tumors.
Radiopharm Theranostics announces the listing of its American Depositary Shares (ADSs) on the Nasdaq Capital Market under the ticker symbol RADX, effective November 27, 2024. Each ADS represents 300 ordinary shares, complementing the company's primary ASX listing. The Nasdaq listing was achieved without an associated capital raise, with Deutsche Bank Trust Company Americas appointed as depositary. Currently, 21% of Radiopharm's shareholders are US-based. The company expects initial trading volume may be as existing shareholders convert ordinary shares to ADSs.
FAQ
What is the current stock price of Radiopharm Theranostics American Depositary Shares (RADX)?
What is the market cap of Radiopharm Theranostics American Depositary Shares (RADX)?
